Vesicor Partners with Black Hawk for Breakthrough in Cancer Therapeutics
Deal News | Apr 28, 2025 | EIN
Black Hawk Acquisition Corp., a special purpose acquisition company, announced a Business Combination Agreement with Vesicor Therapeutics, a biotechnology company focused on p53-based cancer therapeutics. The deal values Vesicor at a $70 million pre-money equity value. The agreement will see Vesicor become a wholly-owned subsidiary of Black Hawk and be listed on Nasdaq under the Vesicor Therapeutics name. Black Hawk's CEO, Kent Kaufman, expressed confidence in Vesicor's potential to disrupt the biotechnology field, emphasizing their strong executive team and growth prospects. Vesicor's first product, ecm-RV/p53, has been administered under Japan's Advanced Medical Care B framework and is set to enter preclinical and clinical trials in the U.S. with an aim to begin by 2026. The transaction, requiring regulatory and shareholder approvals, is expected to conclude in Q4 2025. Legal advisors for the transaction include Celine & Partners, Ogier Global, and PW Richter PLC.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
- Investment
Geography
- United States – Both Black Hawk Acquisition Corp. and Vesicor Therapeutics are based in the United States, and significant corporate activities and clinical trials are set to take place there.
- Japan – Vesicor's unapproved drug candidate has been used in Japan under specific medical provisions, highlighting the country's involvement.
Industry
- Biotechnology – The article discusses Vesicor Therapeutics, a company engaged in the development of biotechnology products specifically focused on cancer therapeutics.
- Pharmaceuticals – Vesicor's work on drug candidates for treating various types of cancer ties them closely to the pharmaceutical sector.
- Healthcare – The development of advanced therapies for cancer aligns Vesicor Therapeutics within the broader healthcare industry.
- Investment – Black Hawk Acquisition Corp. is engaged in mergers and acquisitions, an activity central to the investment industry.
Financials
- $70 million – Pre-money equity value of Vesicor in the business combination with Black Hawk.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Vesicor Therapeutics, Inc. | Target Company | Company | A biotechnology company focused on developing p53-based cancer therapeutics. |
| Black Hawk Acquisition Corp. | Bidding Company | Company | A special purpose acquisition company aiming to merge with Vesicor Therapeutics. |
| Celine & Partners, P.L.L.C. | Legal Advisor to Black Hawk | Company | Legal advisors for Black Hawk in the transaction. |
| Ogier Global (Cayman) Limited | Legal Advisor to Black Hawk | Company | Legal advisors for Black Hawk in the business combination. |
| PW Richter PLC | Legal Advisor to Vesicor | Company | Legal advisors for Vesicor Therapeutics in the transaction. |
| Luo Feng, Ph.D. | Chief Executive Officer and Founder of Vesicor | Person | Founder of Vesicor Therapeutics. |
| Kent Louis Kaufman | Chief Executive Officer and Chairman of Black Hawk | Person | CEO and Chairman of Black Hawk Acquisition Corp. |
| Oded Levy | Board Director of Vesicor | Person | Board Director participating in the transaction discussions. |